Stock GMED GLOBUS MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Globus Medical, Inc.

Equities

GMED

US3795772082

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-09 pm EDT 		5-day change 1st Jan Change
64.36 USD +4.26% Intraday chart for Globus Medical, Inc. +27.50% +20.77%
May. 09 Barclays Adjusts Price Target on Globus Medical to $85 From $83, Maintains Overweight Rating MT
May. 08 Sector Update: Health Care Stocks Slipping Wednesday Afternoon MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,853 6,436 7,326 7,415 7,343 8,692 - -
Enterprise Value (EV) 1 5,542 6,196 6,883 6,969 7,243 7,754 7,251 6,691
P/E ratio 38.7 x 64.6 x 50.1 x 40.1 x 49.8 x 48.3 x 23.2 x 19.5 x
Yield - - - - - - - -
Capitalization / Revenue 7.45 x 8.16 x 7.65 x 7.25 x 4.68 x 3.51 x 3.27 x 3.04 x
EV / Revenue 7.06 x 7.85 x 7.18 x 6.81 x 4.62 x 3.14 x 2.73 x 2.34 x
EV / EBITDA 21.5 x 26.7 x 20.8 x 20.5 x 15.6 x 10.7 x 8.73 x 7.07 x
EV / FCF 54.7 x 45.9 x 31.4 x 66.7 x 43.8 x 8.54 x 9.67 x -
FCF Yield 1.83% 2.18% 3.19% 1.5% 2.28% 11.7% 10.3% -
Price to Book 4.19 x 4.32 x 4.21 x 4.03 x 1.82 x 2.09 x 1.92 x 1.71 x
Nbr of stocks (in thousands) 99,409 98,676 101,471 99,843 137,793 135,057 - -
Reference price 2 58.88 65.22 72.20 74.27 53.29 64.36 64.36 64.36
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 785.4 789 958.1 1,023 1,568 2,473 2,656 2,862
EBITDA 1 257.2 232.2 331.4 339.2 464.1 726.2 830.6 946.6
EBIT 1 172 111.4 172 228 133.1 459.8 530.1 614.4
Operating Margin 21.9% 14.12% 17.95% 22.29% 8.49% 18.59% 19.96% 21.47%
Earnings before Tax (EBT) 1 189.9 125.9 180.4 243 165.4 374.5 506.8 608.4
Net income 1 155.2 102.3 149.2 190.2 122.9 182.3 393.6 473.5
Net margin 19.76% 12.96% 15.57% 18.59% 7.83% 7.37% 14.82% 16.54%
EPS 2 1.520 1.010 1.440 1.850 1.070 1.332 2.773 3.300
Free Cash Flow 1 101.2 135.1 219.4 104.4 165.2 907.5 749.9 -
FCF margin 12.89% 17.13% 22.9% 10.21% 10.53% 36.69% 28.23% -
FCF Conversion (EBITDA) 39.35% 58.2% 66.19% 30.79% 35.6% 124.97% 90.28% -
FCF Conversion (Net income) 65.22% 132.12% 147.04% 54.91% 134.47% 497.78% 190.51% -
Dividend per Share 2 - - - - - - - -
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 250 230.5 263.6 254.1 274.5 276.7 291.6 383.6 616.5 606.7 615.2 606.8 648.4 642.3 661.4
EBITDA 1 85.18 74.34 91.88 82.81 90.16 85.13 96.11 112.9 170 166.6 179.2 177.3 206.2 199.9 204.6
EBIT 1 18.2 46.44 67.78 59.7 54.03 56.4 66.21 0.404 10.12 7.997 113 111.3 138.3 118.5 120.8
Operating Margin 7.28% 20.15% 25.71% 23.49% 19.68% 20.39% 22.71% 0.11% 1.64% 1.32% 18.37% 18.34% 21.32% 18.45% 18.27%
Earnings before Tax (EBT) 1 19.83 48.9 70.54 61.46 62.12 63.19 74.67 2.535 25 -8.558 100.7 97.07 115 109.6 117.1
Net income 1 15.11 38.08 54.59 47.43 50.06 49.13 57.71 0.998 15.04 -7.117 56.13 58.4 80.35 88.55 94.37
Net margin 6.04% 16.52% 20.71% 18.66% 18.24% 17.76% 19.79% 0.26% 2.44% -1.17% 9.12% 9.62% 12.39% 13.79% 14.27%
EPS 2 0.1400 0.3700 0.5300 0.4700 0.4900 0.4800 0.5700 0.0100 0.1100 -0.0500 0.4125 0.4250 0.5425 0.6000 0.6525
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/17/22 5/10/22 8/4/22 11/8/22 2/21/23 5/4/23 8/3/23 11/7/23 2/20/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 311 239 443 446 100 939 1,442 2,001
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 101 135 219 104 165 908 750 -
ROE (net income / shareholders' equity) 13.2% 7.03% 13% 10.6% 9.12% 9.75% 10.5% 11.6%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 14.00 15.10 17.10 18.40 29.30 30.80 33.60 37.70
Cash Flow per Share 2 1.690 1.970 2.670 1.740 2.120 3.180 4.910 -
Capex 70.8 63.7 56.9 74 - - - -
Capex / Sales 9.01% 8.07% 5.94% 7.24% - - - -
Announcement Date 2/20/20 2/17/21 2/17/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Globus Medical, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
64.36 USD
Average target price
67.67 USD
Spread / Average Target
+5.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
GLOBUS MEDICAL, INC. Stock Globus Medical, Inc.
+20.77% 8.69B
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.91% 182B
MEDTRONIC PLC Stock Medtronic plc
+0.46% 110B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.62% 67.92B
DEXCOM, INC. Stock DexCom, Inc.
+3.26% 50.96B
CENCORA, INC. Stock Cencora, Inc.
+9.11% 44.7B
HOYA CORPORATION Stock Hoya Corporation
+2.70% 40.66B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+6.39% 27.6B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.83% 26.63B
TERUMO CORPORATION Stock Terumo Corporation
+13.67% 24.84B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. GMED Stock
  4. Financials Globus Medical, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW